No connection

Search Results

SNYR vs XTLB

SNYR
Synergy CHC Corp.
BEARISH
Price
$0.52
Market Cap
$5.9M
Sector
Healthcare
AI Confidence
95%
XTLB
XTL Biopharmaceuticals Ltd.
BEARISH
Price
$2.44
Market Cap
$5.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
SNYR
--
XTLB
--
Forward P/E
SNYR
1.04
XTLB
--
P/B Ratio
SNYR
-0.26
XTLB
--
P/S Ratio
SNYR
--
XTLB
5.98
EV/EBITDA
SNYR
-3.62
XTLB
--

Profitability

Gross Margin
SNYR
66.83%
XTLB
-232.85%
Operating Margin
SNYR
-219.45%
XTLB
-853.58%
Profit Margin
SNYR
-40.62%
XTLB
0.0%
ROE
SNYR
--
XTLB
-577.13%
ROA
SNYR
-39.89%
XTLB
-240.56%

Growth

Revenue Growth
SNYR
-41.0%
XTLB
--
Earnings Growth
SNYR
--
XTLB
--

Financial Health

Debt/Equity
SNYR
--
XTLB
--
Current Ratio
SNYR
1.22
XTLB
0.7
Quick Ratio
SNYR
0.71
XTLB
0.46

Dividends

Dividend Yield
SNYR
--
XTLB
--
Payout Ratio
SNYR
0.0%
XTLB
0.0%

AI Verdict

SNYR BEARISH

SNYR exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.26, indicating negative shareholders' equity. The company is experiencing a collapse in top-line growth with revenue declining 41% YoY and a catastrophic Q/Q EPS growth of -3600%. Despite a 'strong_buy' analyst consensus and a target price of $6.25, the fundamental data shows a company in a death spiral with a 78.9% one-year price decline and zero earnings beats in the last four quarters.

Strengths
Strong Gross Margin of 66.83%
Current Ratio of 1.22 suggests short-term liquidity is currently maintained
Positive analyst sentiment (though disconnected from fundamentals)
Risks
Negative equity (P/B -0.26) indicating potential insolvency
Severe revenue contraction (-41% YoY)
Extreme earnings volatility and massive misses (Average surprise -1871.45%)
XTLB BEARISH

XTLB exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a complete lack of positive fundamental momentum. The company suffers from catastrophic profitability metrics, including an operating margin of -853.58% and a negative gross margin of -232.85%, indicating a fundamentally broken cost structure. Liquidity is critical with a current ratio of 0.70 and a quick ratio of 0.46, suggesting an inability to meet short-term obligations. Combined with a 0/100 technical trend and an 81.5% decline over five years, the stock presents an extremely high-risk profile.

Strengths
Low current price relative to 52-week high ($10.28)
Positive EPS surprise recorded in historical 2015 data
Micro-cap status allows for high volatility spikes
Risks
Severe liquidity crisis (Current Ratio 0.70)
Extreme negative margins (Operating Margin -853.58%)
Chronic value destruction (5Y Change -81.5%)

Compare Another Pair

SNYR vs XTLB: Head-to-Head Comparison

This page compares Synergy CHC Corp. (SNYR) and XTL Biopharmaceuticals Ltd. (XTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile